October 23rd 2020, 9:45pm
In a presentation during the 27th Annual Prostate Cancer Foundation Scientific Retreat, W. Kevin Kelly, DO, explained the potential of this novel agent and its development progress.
October 23rd 2020, 8:15pm
The combination of ipatasertib and abiraterone acetate achieved a significantly superior radiographic progression-free survival and demonstrated anti-tumor activity compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer with PTEN loss, according to results from the phase 3 IPATential150 clinical trial.
October 23rd 2020, 5:30pm
Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.
October 22nd 2020, 6:15pm
Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.
October 22nd 2020, 6:00pm
In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.
October 11th 2020, 10:15pm
During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.
October 11th 2020, 6:30pm
During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.
October 11th 2020, 3:30pm
In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.
October 11th 2020, 1:00pm
Jens Hillengass, MD, discusses the key takeaways from his presentation at the 2020 National Comprehensive Cancer Network Virtual Congress: Hematologic Malignancies, in which he shared his insights on the diagnostic and staging criteria in multiple myeloma.
October 10th 2020, 10:15pm
The growing use of minimal residual disease as a prognostic marker of progression-free survival and overall survival suggests that it might aid in clinical decision-making.